These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33783581)

  • 21. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple myeloma. An update on diagnosis and management.
    Kyle RA
    Acta Oncol; 1990; 29(1):1-8. PubMed ID: 2178649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
    Hoyos V; Borrello I
    Blood; 2016 Sep; 128(13):1679-87. PubMed ID: 27506540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Multiple myeloma: update on pathophysiology and management].
    Hanamura I; Iida S
    Rinsho Ketsueki; 2018; 59(5):529-538. PubMed ID: 29877243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
    Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
    Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCMA-targeted immunotherapy for multiple myeloma.
    Yu B; Jiang T; Liu D
    J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple Myeloma: Current Advances and Future Directions.
    Martin T; Huff CA
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):255-263. PubMed ID: 31130488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
    Moreau P; Sonneveld P; Boccadoro M; Cook G; Mateos MV; Nahi H; Goldschmidt H; Dimopoulos MA; Lucio P; Bladé J; Delforge M; Hajek R; Ludwig H; Facon T; Miguel JFS; Einsele H
    Haematologica; 2019 Dec; 104(12):2358-2360. PubMed ID: 31439675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.
    Morandi F; Horenstein AL; Costa F; Giuliani N; Pistoia V; Malavasi F
    Front Immunol; 2018; 9():2722. PubMed ID: 30546360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current developments in immunotherapy in the treatment of multiple myeloma.
    Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
    Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of myeloma.
    Smith ML; Newland AC
    QJM; 1999 Jan; 92(1):11-4. PubMed ID: 10209667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunologic approaches for the treatment of multiple myeloma.
    Rasche L; Weinhold N; Morgan GJ; van Rhee F; Davies FE
    Cancer Treat Rev; 2017 Apr; 55():190-199. PubMed ID: 28431262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoptive cell therapy in multiple Myeloma.
    Vallet S; Pecherstorfer M; Podar K
    Expert Opin Biol Ther; 2017 Dec; 17(12):1511-1522. PubMed ID: 28857616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How is patient care for multiple myeloma advancing?
    Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
    Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
    Castella M; Fernández de Larrea C; Martín-Antonio B
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
    Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
    Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnosis and therapy of multiple myeloma: current aspects].
    Betticher DC; Cerny T; Fey MF
    Schweiz Med Wochenschr; 1995 Mar; 125(11):541-51. PubMed ID: 7899848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.